

	डीपीसीओ 2013 के पैरा 4 के तहत, अगस्त 2015 के आंकड़ों के आधारित, मूल्य की संगणना														
	<b>Computation of Ceiling Price based on Aug-2015 Data under Para 4 of DPCO 2013</b>														
									Number of Companies consisting of Market Share of 1% & Above					4	
23.1	Atracurium	Injection 10 mg/ml	Per ML						Sum of MAT value considered for price calculation (in Lakhs)					<b>212.12</b>	
									Sum of PTR per unit considered for price calculation					140.16	
									Number of Packs considered					4	
									Average PTR					<b>35.04</b>	
									Add : 16% Retailer Margin					5.61	
									Ceiling Price (without local taxes) (wef. 10.3.2016)					<b>40.65</b>	
									% Reduction with compared to Highest Price					13.33%	
									WPI Reduction wef 1.4.2016 @ -2.7105%					1.10	
									Final Ceiling Price (without local taxes) (wef. 01.4.2016 or date of notification, whichever is later)					<b>39.55</b>	
													Minimum Price (Rs.)	23.60	
													Maximum Price (Rs.)	40.43	
									<b>Ceiling Price as per NLEM 2011</b>	<b>49.99</b>	<b>Per ML</b>			Average of all considered (Rs.)	35.04
									<b>Deirved Ceiling PTR</b>	<b>43.09</b>				Ceiling Price (Rs.)	40.65
									TOTAL MAT	<b>21,212,212</b>	<b>100.00%</b>				
S. No.	Unique No. as per NLEM	Composition as per NLEM	पैक विवरण Pack Description	छाप BRAND	कंपनी Company	Strength	Pack Size	Unit	PTR (Rs.)	MAT (Rs.)	SKU wise MAT %	Qualify (Y/N) Y=Yes N=No	Price per Unit (Rs.)	Price per Unit (Rs.) Considered	
1	23.1	ATRACURIUM   M3A2	ACRIS 10 MG INJECTION 2.5 ML	ACRIS	GLAND PHARMA LIMITED	10 MG	2.5	ML	95.62	6,883,914	<b>32.45%</b>	Y	<b>38.25</b>	<b>38.25</b>	
2		ATRACURIUM   M3A2	ARTACIL 10 MG INJECTION 5 ML	ARTACIL	NEON LABORATORIES LTD	10 MG	5	ML	117.99	1,324,821	<b>6.25%</b>	Y	<b>23.60</b>	<b>23.60</b>	
3		ATRACURIUM   M3A2	ATCURON 10 MG INJECTION 2.5 ML	ATCURON	SUN PHARMA LABORATORIES LTD.	10 MG	2.5	ML	101.08	8,533,533	<b>40.23%</b>	Y	<b>40.43</b>	<b>40.43</b>	
4		ATRACURIUM   M3A2	TROYCURIUM 10 MG INJECTION 2.5 ML	TROYCURIUM	TROIKAA PHARMACEUTICALS LTD	10 MG	2.5	ML	94.71	4,469,944	<b>21.07%</b>	Y	<b>37.88</b>	<b>37.88</b>	

Computation of Ceiling Price based on Aug 2015 Data under Para 6 of DPCO 2013												
											1	
6.4.3.1.2	ABACAVIR (A)+ LAMIVUDINE (B)	Tablet 60 mg (A) +30 mg (B)	Per Tablet						Number of Companies consisting of Market Share of 1% & Above			
									Sum of MAT value considered for price calculation (in Lakhs)		7.97	
									PTR under Consideration		16.51	
									% Reduction with compared to Highest Price (average)		0.00%	
									Reduction as per Monopoly condition		0.00	
									PTR after Reduction		16.51	
									Add : 16% Retailer Margin		2.64	
									Ceiling Price (without local taxes) (wef. 10.3.2016)		19.15	
									WPI Reduction wef 1.4.2016 @ -2.7105%		0.52	
									Final Ceiling Price (without local taxes) (wef. 01.4.2016 or date of notification, whichever is later)		18.63	
<b>A. List of Item Under consideration</b>									<b>TOTAL MAT</b>	<b>797,328</b>		
S. No.	Unique No. as per NLEM	Composition as per NLEM	वैक विवरण Pack Description	छाप BRAND	कंपनी Company	Strength	Pack Size	Unit	PTR (Rs.)	MAT (Rs.)	MAT (%)	Price per Unit Considered (Rs.)
1	6.4.3.1.2	ABACAVIR + LAMIVUDINE   JSB27	ALBAVIR PED 60/30 MG TABLET 60	ALBAVIR	MYLAN	60/30 MG	60	Tablet	990.47	797,328	100.00%	16.51
<b>B. Computation of Average rate of Reduction under Monopoly</b>												
S. No.	Drug(s)	Strength	Description	Route of Administration/ Dosage Form & packsize/packaging, if any	S.O. number & date	Reduction with reference to the highest PTR under NLEM 2015 (%)						
1	Abacavir (A) + Lamivudine (B)	Tablet 600 mg (A)+ 300 mg (B)	Abacavir (A) + Lamivudine (B)Tablet 600 mg (A)+ 300 mg (B)	Tablet	1817 (E) dated 18.5.2016	0.00						
					<b>Average Reduction</b>	<b>0.00</b>						

Computation of Ceiling Price based on Aug 2015 Data under Para 6 of DPCO 2013												
										Number of Companies consisting of Market Share of 1% & Above	1	
										Sum of MAT value considered for price calculation (in Lakhs)	2.40	
										PTR under Consideration	5.23	
										% Reduction with compared to Highest Price (average)	22.10%	
										Reduction as per Monopoly condition	1.16	
										PTR after Reduction	4.07	
										Add : 16% Retailer Margin	0.65	
										Ceiling Price (without local taxes) (wef. 10.3.2016)	4.72	
										WPI Reduction wef 1.4.2016 @ -2.7105%	0.13	
										Final Ceiling Price (without local taxes) (wef. 01.4.2016 or date of notification, whichever is later)	4.59	
<b>A. List of Item Under consideration</b>										<b>TOTAL MAT</b>	<b>239,789</b>	
S. No.	Unique No. as per NLEM	Composition as per NLEM	पैक विवरण Pack Description	छाप BRAND	कंपनी Company	Strength	Pack Size	Unit	PTR (Rs.)	MAT (Rs.)	MAT (%)	Price per Unit Considered (Rs.)
1	6.4.3.1.3	LAMIVUDINE + STAVUDINE + NEVIRAPINE   J5B30	TRIOMUNE BABY 30/6/50 MG TABLET DT 60	TRIOMUNE	CIPLA LTD.	30/6/50 MG	60	TABLET DT	313.86	239,789	100.00%	5.23
<b>B. Computation of Average rate of Reduction under Monopoly</b>												
S. No.	Drug(s)	Strength	Description	Route of Administration/ Dosage Form & packsize/packaging, if any	S.O. number & date	Reduction with reference to the highest PTR under NLEM 2015 (%)						
1	Lamivudine (A) + Nevirapine (B) + Stavudine (C)	150 mg (A) + 200 mg (B) + 30 mg (C)	Lamivudine (A) + Nevirapine (B) + Stavudine (C) 150 mg (A) + 200 mg (B) + 30 mg (C)	Tablet	4127(E) dated 22.12.2016	22.10						
						Average Reduction	22.1					

Computation of Ceiling Price based on Aug 2015 Data under Para 6 of DPCO 2013												
	6.2.4.11	Pyrazinamide	Oral liquid 250 mg/5 ml	Per ML								
											Number of Companies consisting of Market Share of 1% & Above	
											1	
											Sum of MAT value considered for price calculation (in Lakhs)	
											1.55	
											PTR under Consideration	
											0.53	
											% Reduction with compared to Highest Price (average)	
											8.30%	
											Reduction as per Monopoly condition	
											0.04	
											PTR after Reduction	
											0.49	
											Add : 16% Retailer Margin	
											0.08	
											Ceiling Price (without local taxes) (wef. 10.3.2016)	
											0.57	
											WPI Reduction wef 1.4.2016 @ -2.7105%	
											0.02	
											Final Ceiling Price (without local taxes) (wef. 01.4.2016 or date of notification, whichever is later)	
											0.55	
A. List of Item Under consideration										TOTAL MAT	154,850	
S. No.	Unique No. as per NLEM	Composition as per NLEM	पैक विवरण Pack Description	छाप BRAND	कंपनी Company	Strength	Pack Size	Unit	PTR (Rs.)	MAT (Rs.)	MAT (%)	Price per Unit Considered (Rs.)
1	6.2.4.11	PYRAZINAMIDE   J4A10	PZA CIBA 250 MG SYRUP 100 ML	PZA CIBA	NOVARTIS INDIA LTD	250 MG	100	ML	53.14	154,850	100.00%	0.53
B. Computation of Average rate of Reduction under Monopoly												
S. No.	Drug(s)	Strength	Description	Route of Administration/ Dosage Form & packsize/packing, if any	S.O. number & date	Reduction with reference to the highest PTR under NLEM 2015 (%)						
1	Pyrazinamide	Tablet 500 mg	PyrazinamideTablet 500 mg	Tablet	2195(E) dated 23.6.2016	4.30						
2	Pyrazinamide	Tablet 750 mg	PyrazinamideTablet 750 mg	Tablet	2195(E) dated 23.6.2016	20.75						
3	Pyrazinamide	Tablet 1000 mg	PyrazinamideTablet 1000 mg	Tablet	2195(E) dated 23.6.2016	3.38						
4	Pyrazinamide	Tablet 1500 mg	PyrazinamideTablet 1500 mg	Tablet	2569(E) dated 27.7.2016	4.75						
Average Reduction						8.30						

Computation of Ceiling Price based on Aug 2015 Data under Para 6 of DPCO 2013												
											1	
6.2.2.2	Ciprofloxacin	Oral liquid 250 mg/5ml	Per ML						Number of Companies consisting of Market Share of 1% & Above			
									Sum of MAT value considered for price calculation (in Lakhs)		0.06	
									PTR under Consideration		0.64	
									% Reduction with compared to Highest Price (average)		18.59%	
									Reduction as per Monopoly condition		0.12	
									PTR after Reduction		0.52	
									Add : 16% Retailer Margin		0.08	
									Ceiling Price (without local taxes) (wef. 10.3.2016)		0.60	
									WPI Reduction wef 1.4.2016 @ -2.7105%		0.02	
									Final Ceiling Price (without local taxes) (wef. 01.4.2016 or date of notification, whichever is later)		0.58	
<b>A. List of Item Under consideration</b>									<b>TOTAL MAT</b>	<b>5,978</b>		
S. No.	Unique No. as per NLEM	Composition as per NLEM	पैक विवरण Pack Description	छाप BRAND	कंपनी Company	Strength	Pack Size	Unit	PTR (Rs.)	MAT (Rs.)	MAT (%)	Price per Unit Considered (Rs.)
1	6.2.2.2	CIPROFLOXACIN   J1G1	REBAC 250 MG SYRUP 50 ML	REBAC	HYGEIA PHARMACEUTICALS	250 MG	50	ML	32.14	5,978	100.00%	0.64
<b>B. Computation of Average rate of Reduction under Monopoly</b>												
	S. No.	Drug(s)	Strength	Description	Route of Administration/ Dosage Form & packsize/packaging, if any	S.O. number & date	Reduction with reference to the highest PTR under NLEM 2015 (%)					
	1	Ciprofloxacin	Tablet 250 mg	CiprofloxacinTablet 250 mg	Tablet	1686 (E) dated 9.5.2016	26.87					
	2	Ciprofloxacin	Tablet 500 mg	CiprofloxacinTablet 500 mg	Tablet	1686 (E) dated 9.5.2016	15.61					
	3	Ciprofloxacin	200mg/100ml Injection	Ciprofloxacin200mg/100ml Injection	Injection	443(E) dated 14.2.2017	13.28					
						<b>Average Reduction</b>	<b>18.59</b>					

Computation of Ceiling Price based on Aug 2015 Data under Para 6 of DPCO 2013												
	6.4.3.4.3	Lopinavir (A) + Ritonavir (B)	Tablet 100 mg (A) + 25 mg (B)	Per Tablet					Number of Companies consisting of Market Share of 1% & Above			1
									Sum of MAT value considered for price calculation (in Lakhs)			3.38
									PTR under Consideration			19.66
									% Reduction with compared to Highest Price (average)			1.65%
									Reduction as per Monopoly condition			0.32
									PTR after Reduction			19.34
									Add : 16% Retailer Margin			3.09
									Ceiling Price (without local taxes) (wef. 10.3.2016)			22.43
									WPI Reduction wef 1.4.2016 @ -2.7105%			0.61
									Final Ceiling Price (without local taxes) (wef. 01.4.2016 or date of notification, whichever is later)			21.82
A. List of Item Under consideration										TOTAL MAT	338,496	
S. No.	Unique No. as per NLEM	Composition as per NLEM	पैक विवरण Pack Description	छाप BRAND	कंपनी Company	Strength	Pack Size	Unit	PTR (Rs.)	MAT (Rs.)	MAT (%)	Price per Unit Considered (Rs.)
1	6.4.3.4.3	RITONAVIR + LOPINAVIR   J5B35	EMLETRA JUNIOR 25/100 MG TABLET 60	EMLETRA	EMCURE PHARMACEUTICALS LTD	25/100 MG	60	TABLET	1179.43	338,496	100.00%	19.66
B. Computation of Average rate of Reduction under Monopoly												
		S. No.	Drug(s)	Strength	Description	Route of Administration/ Dosage Form & packsize/packing, if any		S.O. number & date				Reduction with reference to the highest PTR under NLEM 2015 (%)
		1	Lopinavir (A) + Ritonavir (B)	Tablet 200 mg (A) + 50 mg (B)		tablet		1253(E) dated 29.3.2016				1.65
								Average Reduction				1.65

Computation of Ceiling Price based on Aug 2015 Data under Para 6 of DPCO 2013												
											1	
9.1	Levodopa (A) + Carbidopa (B)	CR Tablet 200 mg (A) + 50 (B) mg	Per Tablet								2.72	
											3.62	
											6.55%	
											0.24	
											3.38	
											0.54	
											3.92	
											0.11	
											3.81	
A. List of Item Under consideration										TOTAL MAT	272,197	
S. No.	Unique No. as per NLEM	Composition as per NLEM	पैक विवरण Pack Description	छाप BRAND	कंपनी Company	Strength	Pack Size	Unit	PTR (Rs.)	MAT (Rs.)	MAT (%)	Price per Unit Considered (Rs.)
1	9.1	LEVODOPA + CARBIDOPA   N4A6	TIDOMET 200/50 MG TABLET CR 10	TIDOMET	TORRENT PHARMACEUTICALS LTD.	200/50 MG	10	TABLET CR	36.18	272,197	100.00%	3.62
B. Computation of Average rate of Reduction under Monopoly												
S. No.	Drug(s)	Strength	Description	Route of Administration/ Dosage Form & packsize/packaging, if any	S.O. number & date	Reduction with reference to the highest PTR under NLEM 2015 (%)						
1	Levodopa (A) + Carbidopa (B)	CR Tablet 100 mg (A) + 25 mg (B)		Tablet	1253(E) dated 29.3.2016	24.03%						
2	Levodopa (A) + Carbidopa (B)	100mg+25mg Tablet		Tablet	1819 (E) dated 18.5.2016	1.06%						
3	Levodopa (A) + Carbidopa (B)	100mg +10 mg Tablet		Tablet	1819 (E) dated 18.5.2016	0.78%						
4	Levodopa (A) + Carbidopa (B)	250/25 MG tablet		Tablet	2693(E) dated 15.09.2016	0.32%						
						Average Reduction					6.55%	

Computation of Ceiling Price based on Aug 2015 Data under Para 6 of DPCO 2013												
											Number of Companies consisting of Market Share of 1% & Above	1
8.3.2	Cyclosporine	Injection 50 mg/ml	Per ML								Sum of MAT value considered for price calculation (in Lakhs)	7.16
											PTR under Consideration	255.81
											% Reduction with compared to Highest Price (average)	16.86%
											Reduction as per Monopoly condition	43.13
											PTR after Reduction	212.68
											Add : 16% Retailer Margin	34.03
											Ceiling Price (without local taxes) (wef. 10.3.2016)	246.71
											WPI Reduction wef 1.4.2016 @ -2.7105%	6.69
											Final Ceiling Price (without local taxes) (wef. 01.4.2016 or date of notification, whichever is later)	240.02
<b>A. List of Item Under consideration</b>											<b>TOTAL MAT</b>	<b>715,976</b>
S. No.	Unique No. as per NLEM	Composition as per NLEM	पैक विवरण Pack Description	छाप BRAND	कंपनी Company	Strength	Pack Size	Unit	PTR (Rs.)	MAT (Rs.)	MAT (%)	Price per Unit Considered (Rs.)
1	8.3.2	CYCLOSPORIN   L4A4	SANDIMMUN 50 MG INJECTION 1 ML	SANDIMMUN	NOVARTIS INDIA LTD	50 MG	1	ML	255.81	715,976	100.00%	255.81
<b>B. Computation of Average rate of Reduction under Monopoly</b>												
S. No.	Drug(s)	Strength	Description	Route of Administration/ Dosage Form & packsize/packaging, if any	S.O. number & date	Reduction with reference to the highest PTR under NLEM 2015 (%)						
1	Cyclosporine	Capsule 100 mg		Capsule	2195(E) dated 23.6.2016	19.24						
2	Cyclosporine	Capsule 50 mg		Capsule	2195(E) dated 23.6.2016	9.60						
3	Cyclosporine	Oral liquid 100 mg/ml		Oral liquid	2731(E) dated 17.8.2016	30.71						
4	Cyclosporine	25 MG capsule		Capsule	2693(E) dated 15.09.2016	7.90						
						<b>Average Reduction</b>	<b>16.86</b>					







Computation of Ceiling Price based on Aug 2015 Data under Para 6 of DPCO 2013												
											1	
2.2.3	Tramadol	100 mg capsule	Per Capsule									
											Number of Companies consisting of Market Share of 1% & Above	
											Sum of MAT value considered for price calculation (in Lakhs)	
											0.23	
											PTR under Consideration	
											10.66	
											% Reduction with compared to Highest Price (average)	
											25.96%	
											Reduction as per Monopoly condition	
											2.77	
											PTR after Reduction	
											7.89	
											Add : 16% Retailer Margin	
											1.26	
											Ceiling Price (without local taxes) (wef. 10.3.2016)	
											9.15	
											WPI Reduction wef 1.4.2016 @ -2.7105%	
											0.25	
											Final Ceiling Price (without local taxes) (wef. 01.4.2016 or date of notification, whichever is later)	
											8.90	
<b>A. List of Item Under consideration</b>										<b>TOTAL MAT</b>	<b>22,608</b>	
S. No.	Unique No. as per NLEM	Composition as per NLEM	पैक विवरण Pack Description	छाप BRAND	कंपनी Company	Strength	Pack Size	Unit	PTR (Rs.)	MAT (Rs.)	MAT (%)	Price per Unit Considered (Rs.)
1	2.2.3	TRAMADOL   N2B5	TAKOL CR 100 MG CAPSULE CR 10	TAKOL CR	RAPTAKOS, BRETT & CO. LTD.	100 MG	10	CAPSULE CR	106.64	22,608	100.00%	10.66
<b>B. Computation of Average rate of Reduction under Monopoly</b>												
S. No.	Drug(s)	Strength	Description	Route of Administration/ Dosage Form & packsize/packing, if any	S.O. number & date	Reduction with reference to the highest PTR under NLEM 2015 (%)						
1	Tramadol	50 mg capsule	50 mg capsule	Capsule	S.O. No. 2195 (E) dated 23.06.2016	32.73						
2	Tramadol	50mg/ml	1 ML & 2 ML Pack	Injection	<b>Proposed in current 43th meeting</b>	22.57						
3	Tramadol	50mg/ml	20 ML Pack	Injection	<b>Proposed in current 43th meeting</b>	22.57						
<b>Average Reduction</b>						<b>25.96</b>						









Computation of Ceiling Price based on Aug 2015 Data under Para 6 of DPCO 2013												
											1	
21.3.2	Levonorgestrel	Tablet 0.75 mg	Per tablet						Number of Companies consisting of Market Share of 1% & Above			
									Sum of MAT value considered for price calculation (in Lakhs)		4102.98	
									PTR under Consideration		32.00	
									% Reduction with compared to Highest Price (average)		3.63%	
									Reduction as per Monopoly condition		1.16	
									PTR after Reduction		30.84	
									Add : 16% Retailer Margin		4.93	
									Ceiling Price (without local taxes) (wef. 10.3.2016)		35.77	
									WPI Reduction wef 1.4.2016 @ -2.7105%		0.97	
									Final Ceiling Price (without local taxes) (wef. 01.4.2016 or date of notification, whichever is later)		34.80	
A. List of Item Under consideration										TOTAL MAT	412,694,557	100.00%
S. No.	Unique No. as per NLEM	Composition as per NLEM	वैक विवरण Pack Description	छाप BRAND	कंपनी Company	Strength	Pack Size	Unit	PTR (Rs.)	MAT (Rs.)	MAT (%)	Price per Unit Considered (Rs.)
1	21.3.2	LEVONORGESTREL   G3A13	UNWANTED 72 0.75 MG TABLET 2	UNWANTED 72	MANKIND PHARMACEUTICALS LTD.	0.75 MG	2	TABLET	64.00	410,297,792	99.42%	32.00
		LEVONORGESTREL   G3A13	NORLEVO 0.75 MG TABLET 2	NORLEVO	WIN-MEDICARE PVT. LTD.	0.75 MG	2	TABLET	39.28	2,396,765	0.58%	
B. Computation of Average rate of Reduction under Monopoly												
	S. No.	Drug(s)	Strength	Description	Route of Administration/ Dosage Form & packsize/packaging, if any	S.O. number & date	Reduction with reference to the highest PTR under NLEM 2015 (%)					
	1	Ethinylestradiol	Tablet 0.01 mg	Tablet 0.01 mg	tablet	S.O. No. 2569 (E) dated 29.07.2016	3.63					
	2	Ethinylestradiol	Tablet 0.05 mg	Tablet 0.05 mg	tablet	S.O. No. 4127 (E) dated 22.12.2016	3.63					
						<b>Average Reduction</b>	<b>3.63</b>					



Computation of Ceiling Price based on Aug 2015 Data under Para 6 of DPCO 2013												
												1
21.1.3	Hydrocortisone	Tablet 10 mg	Per Tablet						Number of Companies consisting of Market Share of 1% & Above			
									Sum of MAT value considered for price calculation (in Lakhs)			172.30
									PTR under Consideration			5.36
									% Reduction with compared to Highest Price (average)			13.19%
									Reduction as per Monopoly condition			0.71
									PTR after Reduction			4.65
									Add : 16% Retailer Margin			0.74
									Ceiling Price (without local taxes) (wef. 10.3.2016)			5.39
									WPI Reduction wef 1.4.2016 @ -2.7105%			0.15
									Final Ceiling Price (without local taxes) (wef. 01.4.2016 or date of notification, whichever is later)			5.24
A. List of Item Under consideration										TOTAL MAT	17,229,613	
S. No.	Unique No. as per NLEM	Composition as per NLEM	पैक विवरण Pack Description	छाप BRAND	कंपनी Company	Strength	Pack Size	Unit	PTR (Rs.)	MAT (Rs.)	MAT (%)	Price per Unit Considered (Rs.)
1	21.1.3	HYDROCORTISONE   H2A7	HISONE(SMR) 10 MG TABLET 10	HISONE(SMR)	SAMARTH LIFE SCIENCES PVT LTD	10 MG	10	TABLET	53.60	17,229,613	100.00%	5.36
B. Computation of Average rate of Reduction under Monopoly												
S. No.	Drug(s)	Strength	Description	Route of Administration/ Dosage Form & packsize/packing, if any	S.O. number & date	Reduction with reference to the highest PTR under NLEM 2015 (%)						
1	Hydrocortisone	Injection 100 mg/ml	Injection 100 mg/ml	injection	S.O. No. 1686 (E) dated 09.05.2016	13.19						
Average Reduction						13.19						

Computation of Ceiling Price based on Aug 2015 Data under Para 6 of DPCO 2013												
												1
21.1.3	Hydrocortisone	Tablet 5 mg	Per Tablet						Number of Companies consisting of Market Share of 1% & Above			
									Sum of MAT value considered for price calculation (in Lakhs)			95.53
									PTR under Consideration			2.76
									% Reduction with compared to Highest Price (average)			13.19%
									Reduction as per Monopoly condition			0.36
									PTR after Reduction			2.40
									Add : 16% Retailer Margin			0.38
									Ceiling Price (without local taxes) (wef. 10.3.2016)			2.78
									WPI Reduction wef 1.4.2016 @ -2.7105%			0.08
									Final Ceiling Price (without local taxes) (wef. 01.4.2016 or date of notification, whichever is later)			2.70
A. List of Item Under consideration										TOTAL MAT	9,553,095	
S. No.	Unique No. as per NLEM	Composition as per NLEM	पैक विवरण Pack Description	छाप BRAND	कंपनी Company	Strength	Pack Size	Unit	PTR (Rs.)	MAT (Rs.)	MAT (%)	Price per Unit Considered (Rs.)
1	21.1.3	HYDROCORTISONE   H2A7	HISONE(SMR) 5 MG TABLET 10	HISONE(SMR)	SAMARTH LIFE SCIENCES PVT LTD	5 MG	10	TABLET	27.62	9,553,095	100.00%	2.76
B. Computation of Average rate of Reduction under Monopoly												
S. No.	Drug(s)	Strength	Description	Route of Administration/ Dosage Form & packsize/packing, if any	S.O. number & date	Reduction with reference to the highest PTR under NLEM 2015 (%)						
1	Hydrocortisone	Injection 100 mg/ml	Injection 100 mg/ml	injection	S.O. No. 1686 (E) dated 09.05.2016	13.19						
Average Reduction						13.19						